Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?
Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?
Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?
Submitted by
admin
on August 13, 2013 - 11:06am
Source:
Motley Fool
News Tags:
IPOs
Intrexon
Eli Lilly
synthetic DNA
Headline:
Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?
Do Not Allow Advertisers to Use My Personal information
